A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary

Simply Wall St.

Mar 12

Recent commentary from Barclays on Jazz Pharmaceuticals (JAZZ) has put fresh attention on the stock, after the bank highlighted the durability of its central nervous system therapies and record fourth...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2618065419"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618065419\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618065419?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-12 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618065419","market":"sg","top_or_hot":-1,"title":"A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary","media":"Simply Wall St.","content":"<div>\n<p>Recent commentary from Barclays on Jazz Pharmaceuticals (JAZZ) has put fresh attention on the stock, after the bank highlighted the durability of its central nervous system therapies and record fourth...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/a-look-at-jazz-pharmaceuticals-jazz-valuation-after-record-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/a-look-at-jazz-pharmaceuticals-jazz-valuation-after-record-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent commentary from Barclays on Jazz Pharmaceuticals (JAZZ) has put fresh attention on the stock, after the bank highlighted the durability of its central nervous system therapies and record fourth...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/a-look-at-jazz-pharmaceuticals-jazz-valuation-after-record-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/a-look-at-jazz-pharmaceuticals-jazz-valuation-after-record-r","article_id":"2618065419","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jazz/jazz-pharmaceuticals/news/a-look-at-jazz-pharmaceuticals-jazz-valuation-after-record-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618065419","pubTimestamp":1773282195,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent commentary from Barclays on Jazz Pharmaceuticals (JAZZ) has put fresh attention on the stock, after the bank highlighted the durability of its central nervous system therapies and record fourth quarter revenue tied to Xywav, Epidiolex, and Modeyso.\nSee our latest analysis for Jazz Pharmaceuticals.\nAt a share price of US$185.43, Jazz has given investors a 12.38% 1 month share price return and a 38.22% 1 year total shareholder return. This suggests that recent revenue headlines and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"在创纪录的收入和巴克莱的支持性评论之后，看看Jazz Pharmaceuticals(JAZZ)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1.5},"content_text":"Recent commentary from Barclays on Jazz Pharmaceuticals (JAZZ) has put fresh attention on the stock, after the bank highlighted the durability of its central nervous system therapies and record fourth quarter revenue tied to Xywav, Epidiolex, and Modeyso. See our latest analysis for Jazz Pharmaceuticals. At a share price of US$185.43, Jazz has given investors a 12.38% 1 month share price return and a 38.22% 1 year total shareholder return. This suggests that recent revenue headlines and product commentary may be contributing to current momentum rather than fading enthusiasm. If this news has you looking beyond a single name, it could be a good time to broaden your watchlist with 34 healthcare AI stocks and see what else is gaining attention in the sector. With Jazz trading at US$185.43 and screens flagging both a value score of 6 and an intrinsic discount, the key question is whether current sentiment leaves upside on the table or whether markets are already fully pricing in future growth. AdvertisementMost Popular Narrative: 19% Undervalued According to Vestra, the fair value of Jazz Pharmaceuticals sits at $228.98 versus the last close of $185.43. This frames the current debate around whether the market is fully appreciating its diversified revenue mix and oncology pivot.  Jazz Pharmaceuticals has officially entered a new era of \"blockbuster\" diversification, closing out 2025 with its highest quarterly revenue ever. On February 24, 2026, the company reported Q4 revenue of $1.20 billion, a 10% year-over-year increase that beat analyst estimates. This was driven by a powerful combination of Xywav ($1.7 billion for the full year, up 12%) and Epidiolex, which officially hit its $1.1 billion milestone. Despite the record beat, the stock remains around $182.01 as investors weigh the slightly conservative 2026 revenue guidance of $4.25 billion to $4.50 billion, which falls just below some previous \"whisper\" estimates.  Read the complete narrative. Curious how a record year in sleep and epilepsy, a ramping oncology franchise, and fresh guidance combine into one valuation story? The core tension sits between cash rich operations, heavier R&D, and how much credit the narrative gives to future oncology contribution. If you want to see exactly which revenue mix and margin assumptions plug into that $228.98 figure, the full breakdown is where it all comes together. Result: Fair Value of $228.98 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on oncology execution and regulatory timelines. Any setback on zanidatamab or weaker than expected Modeyso uptake could quickly cool the current enthusiasm. Find out about the key risks to this Jazz Pharmaceuticals narrative. Next Steps If this mix of optimism and caution around Jazz feels familiar, take a moment now to weigh the full picture for yourself with 4 key rewards and 2 important warning signs Looking for more investment ideas? Before you move on, lock in this momentum by lining up your next watchlist candidates with a few focused screens that surface targeted opportunities.  Target potential mispricings by scanning 50 high quality undervalued stocks that pair strong fundamentals with attractive entry points. Prioritise resilience by filtering for 67 resilient stocks with low risk scores that aim to keep portfolio swings in check. Get ahead of the crowd by reviewing a screener containing 23 high quality undiscovered gems that most investors may not be watching yet.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}